首页> 美国卫生研究院文献>other >Rapid Phenotypic and Genomic Change in Response to Therapeutic Pressure in Prostate Cancer Inferred by High Content Analysis of Single Circulating Tumor Cells
【2h】

Rapid Phenotypic and Genomic Change in Response to Therapeutic Pressure in Prostate Cancer Inferred by High Content Analysis of Single Circulating Tumor Cells

机译:通过单循环肿瘤细胞的高含量分析推断前列腺癌对治疗压力的快速表型和基因组变化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Timely characterization of a cancer's evolution is required to predict treatment efficacy and to detect resistance early. High content analysis of single Circulating Tumor Cells (CTCs) enables sequential characterization of genotypic, morphometric and protein expression alterations in real time over the course of cancer treatment. This concept was investigated in a patient with castrate-resistant prostate cancer progressing through both chemotherapy and targeted therapy. In this case study, we integrate across four timepoints 41 genome-wide copy number variation (CNV) profiles plus morphometric parameters and androgen receptor (AR) protein levels. Remarkably, little change was observed in response to standard chemotherapy, evidenced by the fact that a unique clone (A), exhibiting highly rearranged CNV profiles and AR+ phenotype was found circulating before and after treatment. However, clinical response and subsequent progression after targeted therapy was associated with the drastic depletion of clone A, followed by the sequential emergence of two distinct CTC sub-populations that differed in both AR genotype and expression phenotype. While AR- cells with flat or pseudo-diploid CNV profiles (clone B) were identified at the time of response, a new tumor lineage of AR+ cells (clone C) with CNV altered profiles was detected during relapse. We showed that clone C, despite phylogenetically related to clone A, possessed a unique set of somatic CNV alterations, including MYC amplification, an event linked to hormone escape. Interesting, we showed that both clones acquired AR gene amplification by deploying different evolutionary paths. Overall, these data demonstrate the timeframe of tumor evolution in response to therapy and provide a framework for the multi-scale analysis of fluid biopsies to quantify and monitor disease evolution in individual patients.
机译:为了预测治疗效果并及早发现耐药性,需要及时表征癌症的进展。对单个循环肿瘤细胞(CTC)的高含量分析可在癌症治疗过程中实时地实时表征基因型,形态和蛋白质表达的变化。在通过化学疗法和靶向疗法都进展的去势抵抗性前列腺癌患者中研究了这一概念。在本案例研究中,我们跨四个时间点整合了41个全基因组拷贝数变异(CNV)配置文件,形态参数和雄激素受体(AR)蛋白水平。值得注意的是,对标准化学疗法的反应几乎没有观察到变化,这是由以下事实证明的:在治疗前后发现了表现出高度重排的CNV谱和AR +表型的独特克隆(A)。但是,靶向治疗后的临床反应和随后的进展与克隆A的急剧耗竭有关,随后依次出现了两个不同的CTC亚群,它们在AR基因型和表达表型上都不同。虽然在反应时鉴定出具有平坦或假二倍体CNV谱的AR细胞(克隆B),但在复发期间发现了CNV改变谱的AR +细胞新肿瘤谱系(克隆C)。我们显示,尽管克隆C与克隆A在系统发育上相关,但它具有一组独特的体细胞CNV改变,包括MYC扩增(与激素逃逸有关的事件)。有趣的是,我们表明两个克隆都通过部署不同的进化途径获得了AR基因扩增。总体而言,这些数据表明了肿瘤对治疗的反应时间框架,并为液体活检的多尺度分析提供了框架,以量化和监测单个患者的疾病进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号